Prograf Indication For Unrelated Donor BMT Requires Confirmatory Trial
Executive Summary
Fujisawa's Prograf could receive an indication for the prevention of graft versus host disease in patients receiving unrelated donor bone marrow transplants after a confirmatory trial, FDA's Oncologic Drugs Advisory Committee suggested Jan. 12.